Analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to post ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have issued estimates for Keryx Biopharmaceuticals’ earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.11). Keryx Biopharmaceuticals posted earnings per share of ($0.20) during the same quarter last year, which suggests a positive year over year growth rate of 35%. The business is expected to report its next earnings results on Tuesday, November 6th.

On average, analysts expect that Keryx Biopharmaceuticals will report full-year earnings of ($0.61) per share for the current fiscal year, with EPS estimates ranging from ($0.63) to ($0.58). For the next fiscal year, analysts forecast that the company will report earnings of ($0.01) per share, with EPS estimates ranging from ($0.33) to $0.36. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.02).

Several brokerages have issued reports on KERX. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. HC Wainwright set a $9.00 price objective on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 23rd. BidaskClub upgraded shares of Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 23rd. Finally, Citigroup cut their price objective on shares of Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $6.25.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KERX. Deutsche Bank AG raised its position in shares of Keryx Biopharmaceuticals by 103.2% in the fourth quarter. Deutsche Bank AG now owns 205,933 shares of the biopharmaceutical company’s stock valued at $956,000 after buying an additional 104,585 shares in the last quarter. Mackay Shields LLC acquired a new stake in shares of Keryx Biopharmaceuticals in the first quarter valued at approximately $294,000. Swiss National Bank raised its position in shares of Keryx Biopharmaceuticals by 13.0% in the first quarter. Swiss National Bank now owns 160,600 shares of the biopharmaceutical company’s stock valued at $657,000 after buying an additional 18,500 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Keryx Biopharmaceuticals by 3.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 536,951 shares of the biopharmaceutical company’s stock valued at $2,197,000 after buying an additional 17,620 shares in the last quarter. Finally, Meridian Wealth Management LLC acquired a new stake in shares of Keryx Biopharmaceuticals in the first quarter valued at approximately $203,000. Institutional investors own 59.53% of the company’s stock.

KERX stock traded down $0.01 during mid-day trading on Wednesday, hitting $2.99. 631,400 shares of the company were exchanged, compared to its average volume of 1,154,585. The company has a quick ratio of 1.40, a current ratio of 2.28 and a debt-to-equity ratio of -3.16. The company has a market capitalization of $383.06 million, a PE ratio of -3.44 and a beta of 2.52. Keryx Biopharmaceuticals has a 1-year low of $2.93 and a 1-year high of $8.07.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Featured Story: Risk Tolerance and Your Investment Decisions

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.